Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pembrolizumab in Combination With Xelox Bevacizumab in Patients With Microsatellite Stable Mestatic Colorectal Cancer and a High Immune Infiltrate : a Proof of Concept Study

NCT04262687 is registered in ClinicalTrials.gov with Federation Francophone de Cancerologie Digestive as lead sponsor.

NCT NCT04262687
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04262687 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pembrolizumab in Combination With Xelox Bevacizumab in Patients With Microsatellite Stable Mestatic Colorectal Cancer and a High Immune Infiltrate : a Proof of Concept Study
Lead sponsor
Federation Francophone de Cancerologie Digestive
Phase
Phase 2
Overall status
Unknown status
Start date
April 6, 2021
Completion date
September 30, 2024
Enrollment
55 (estimated)
Sites
88

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer metastatic, high immune infiltrate, microsatellite stable